What laboratory tests are used to diagnose an insulinoma (insulin-producing tumor)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 30, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

To diagnose insulinoma, a supervised 72-hour fast with serial measurements of blood glucose, insulin, C-peptide, and proinsulin levels is the most important laboratory test, as it is the gold standard for diagnosis. During the fast, if hypoglycemia occurs (blood glucose <45-50 mg/dL) with inappropriately elevated insulin (≥3 μU/mL), elevated C-peptide (≥0.6 ng/mL), and elevated proinsulin (≥5 pmol/L), this strongly suggests insulinoma 1. Additional helpful tests include measuring beta-hydroxybutyrate levels, which are typically suppressed in insulinoma, and sulfonylurea screening to rule out factitious hypoglycemia.

Key Laboratory Tests

  • Serum insulin
  • Proinsulin
  • C peptide
  • Blood glucose
  • Beta-hydroxybutyrate levels
  • Sulfonylurea screening The 72-hour fast should be conducted in a hospital setting with close monitoring, as dangerous hypoglycemia may occur. Most insulinoma patients develop hypoglycemia within 24-48 hours of fasting. These tests are crucial because insulinomas cause inappropriate insulin secretion independent of blood glucose levels, leading to the paradoxical finding of detectable insulin levels during hypoglycemia, which wouldn't occur in normal physiology where insulin secretion should be suppressed when blood glucose is low. Multiphasic CT or MRI scans should also be performed to rule out metastatic disease 1.

From the Research

Labs to Check for Insulinoma

To diagnose insulinoma, several laboratory tests can be used, including:

  • Fasting test: a 48-hour or 72-hour fast to demonstrate Whipple's triad, which consists of symptoms known or likely to be caused by hypoglycemia, a low plasma glucose measured at the time of the symptoms, and relief of symptoms when the glucose is raised to normal 2, 3, 4
  • Oral glucose tolerance test (OGTT): a 5-hour OGTT to evaluate the ratios of serum concentrations of insulin and C-peptide to glucose 5
  • Glucagon stimulation test: to assess the insulin response to glucagon, which can be useful in diagnosing insulinoma, especially in cases with normal results from prolonged fast 6
  • Measurement of serum insulin, C-peptide, and proinsulin levels: to assess the insulin secretion and diagnose insulinoma 2, 3, 4

Diagnostic Criteria

The diagnostic criteria for insulinoma include:

  • Demonstration of Whipple's triad during a supervised fast
  • Elevated serum insulin, C-peptide, and proinsulin levels during hypoglycemia
  • Insulin/C-peptide ratio below 1.0
  • Relief of symptoms when glucose is raised to normal

Test Performance

The performance of these tests varies, with:

  • The 48-hour fast having a high sensitivity and specificity for diagnosing insulinoma 2
  • The 5-hour OGTT having a sensitivity of 82.67% and specificity of 73.08% for diagnosing insulinoma 5
  • The prolonged fasting test having a sensitivity of 88.9% and specificity of 100% for diagnosing insulinoma 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Forty-eight-hour fast: the diagnostic test for insulinoma.

The Journal of clinical endocrinology and metabolism, 2000

Research

ANTHROPOMETRIC FEATURES ARE NOT PREDICTIVE OF 72-HOUR FAST DURATION IN INSULINOMAS.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2017

Research

Insulinoma in a patient with normal results from prolonged fast and glucagon-induced hypoglycemia.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2010

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.